Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
First-in-human study starts include radioligands from Akiram and Philogen.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
